Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials,Expert Review of Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Expert Rev. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Expert Review of Gastroenterology & Hepatology ( IF 3.9 ) Pub Date : 2024-03-21 , DOI: 10.1080/17474124.2024.2326838
Rish K. Pai ₁ , Geert D’Haens ₂ , Taku Kobayashi ₃ , Bruce E. Sands ₄ , Simon Travis ₅ , Vipul Jairath ₆ , Gert De Hertogh ₇ , Bomina Park ₈ , Kim McGinnis ₈ , Isabel Redondo ₈ , Nicole G. Lipitz ₉ , Theresa Hunter Gibble ₈ , Fernando Magro ₁₀

Affiliation

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, USA
Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Centers, Amsterdam, Netherlands
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Kennedy Institute and Biomedical Research Centre, University of Oxford, Oxford, UK
Division of Gastroenterology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Department of Pathology, University Hospitals Leuven, Leuven, Belgium
Eli Lilly and Company, Indianapolis, IN, USA
Syneos Health, San Diego, CA, USA
CINTESIS@RISE, Departmento, Faculty of Medicine of the University of Porto, Porto, Portugal

Treatment goals for ulcerative colitis (UC) are evolving from the achievement of clinical remission to more rigorous goals defined by endoscopic and histologic healing. Achievement of deeper remiss...

中文翻译：